Key takeaways Zepbound (tirzepatide) is an FDA-approved prescription medicine for chronic weight management and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity; it carries a boxed warning and several precautions, so safety is provider-determined and individual. The boxed warning for thyroid C-cell tumors comes from rat studies; the FDA label states […]
Key takeaways Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist, while semaglutide (Wegovy, Ozempic) acts on the GLP-1 receptor alone — this is the core pharmacological difference. In SURMOUNT-5, the head-to-head obesity trial, tirzepatide produced a greater average weight reduction than semaglutide (-20.2% vs -13.7% at 72 weeks); these are trial averages and individual […]
Key takeaways The most common tirzepatide side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation, decreased appetite) — in clinical trials these were generally mild-to-moderate, transient, and most frequent during dose escalation. GI side-effect rates differ by population: in pooled type 2 diabetes trials the FDA label reports nausea up to 18% at 15 mg, while […]
Key takeaways Yes — Zepbound and Mounjaro contain the same active ingredient, tirzepatide, made by the same manufacturer (Eli Lilly), in the same six dose strengths, with the same boxed warning. The core difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes glycemic control; Zepbound is approved for chronic weight management and, […]
Key takeaways According to the FDA-approved labels for Zepbound and Mounjaro, tirzepatide typically starts at 2.5 mg injected under the skin once weekly for 4 weeks, then may step up in 2.5 mg increments no more often than every 4 weeks, to a maximum of 15 mg once weekly. The 2.5 mg starting dose is […]
Key takeaways The peptides with real human evidence for weight loss are the GLP-1 medications: semaglutide (Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Zepbound), both FDA-approved for chronic weight management. In trials, semaglutide averaged about 15% body-weight reduction and tirzepatide up to about 20%; these are population averages from the branded products, not promises, and […]
